Join experts from ProteoGenix and Eurofins as they share strategies and solutions to streamline stable cell line development, ensuring high yields, clonal homogeneity, and seamless GMP transitions for biopharmaceutical success.
Stable cell line development is a critical step in creating new biopharmaceuticals and immunodiagnostics. Achieving stable and durable expression, high clonal homogeneity, and strong yield can profoundly impact the success of downstream development. However, numerous challenges make this process both complex and high-risk.
In this webinar, experts from ProteoGenix (CRO) and Eurofins (CMO) discuss the key challenges in stable cell line development and share actionable strategies to overcome them. Learn how to select a trusted partner and discover why close collaboration between a CRO specialized in stable cell lines and a CMO ensures a seamless transition to GMP manufacturing success.
Key Topics Include:
- The importance of stable cell line development in large-scale antibody production
- Overcoming key challenges in the development process
- Choosing the right approach and partners for this critical phase
- How a seamless partnership between CROs and CDMOs streamlines the path to GMP compliance
Don’t miss this opportunity to lay the groundwork for a successful CLD project and make informed decisions that will drive your project’s success!
Click to watch the webinar recording. To view the presentation full screen simply click the square icon located in the bottom-right corner of the video-viewer.
Presenters
Senior Account Manager - Recombinant Protein & Antibody Production
ProteoGenix CRO
Laura leads the Account Management team in the Recombinant Protein and Antibody Production Department at ProteoGenix. With a Ph.D. in Molecular Biophysics, she has completed postdoctoral research at IGBMC in Strasbourg and the University of Cambridge.
Her expertise lies in recombinant antibody production, stable cell line development, and managing complex scientific projects. Laura combines her deep understanding of molecular biology, protein biochemistry, and structural biology with over five years of industry experience to deliver tailored biotech solutions.
Senior Director of Business Development
Eurofins CDMO
Jo serves as the Senior Director of Business Development at Eurofins CDMO, where he leads the sales and technical team. With a Ph.D. in Biophysical Biochemistry from the University of Leuven in Belgium, Jo has a robust background as a biochemist. He dedicated over six years to Ablynx, managing teams in both the Discovery and CMC groups. For more than 12 years, Jo has been at Eurofins, overseeing various teams in analytics, formulation, and sales. His extensive experience in the pharma sector has involved numerous projects, and he is committed to finding innovative solutions to support clients in the early phases of clinical development.
Production Partner
ProteoGenix
Founded in 2003, ProteoGenix has evolved from its roots in developing diagnostic assays and biotherapeutics to become a leading contract research organization and a trusted partner in the biopharma industry. With a focus on high-quality antibodies and proteins, the company plays a pivotal role in advancing biomolecules from early discovery to clinical applications. Offering comprehensive services in six key areas—antibody engineering, bioprocess development, monoclonal and polyclonal antibody development, recombinant protein and antibody production, gene synthesis, and peptide synthesis—ProteoGenix is a one-stop solution for researchers and developers. With over 15 years of experience, innovative R&D contributions like the XtenCHO™ cell line, and an extensive catalog of over 200,000 products, ProteoGenix stands as a cornerstone in the life sciences community, dedicated to improving the success rate of clinical applications in biopharma.
Additional Content From ProteoGenix
Overcome the Multiple Challenges of Neutralizing Antibodies in Cancer Therapy Using Innovative Phage Display Technologies
In this webinar, Dr. Conor McCartin discusses how phage display can be used for human antibody development.
Additional Content From Scientist.com
How to Avoid Expensive Redesign Cycles in Antibody Discovery
Learn how integrated antibody discovery and engineering strategies can accelerate the path from hit to optimized lead in less than 12 months while minimizing costly redesign cycles.
Beyond Exposure: Integrating PK/PD for Translational Predictive Power
Learn to integrate PK/PD modeling and strategic biomarkers to bridge the translational gap. Improve clinical predictability for NCEs, ADCs, and large molecules in this technical webinar.
Advancing the Manufacture of Mesenchymal Stromal Cells and Derived Extracellular Vesicles in Stirred-Tank Bioreactors Through Enhanced Bioprocess Control
Learn how to scale the production of MSCs and extracellular vesicles using bioreactor control and real-time monitoring for more consistent therapies.
Related Content
Advancing ADC Development: Leveraging AI and Translational Preclinical Models to Improve Clinical Predictability
Join our webinar to discover how to de-risk ADC development through the integration of AI-driven analytics, mouse clinical trials and specialized translational models.
From Biopsy to Better Decisions: Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
Learn how patient-derived organoids predict treatment response in metastatic colorectal cancer and explore findings from the OPTIC study on drug sensitivity and clinical outcomes.
De-Risking Immunotherapy Targets with Next-Gen HLA Discovery Platforms
In this webinar, Rico Buchli, PhD, shares how next-generation soluble HLA peptide discovery platforms can strengthen early immunotherapy R&D - from target identification and confirmation to receptor/drug validation and translational decision-making.